IDP Pharma will present at the Annual Meeting of the American Association for Cancer Research (June 22-24) its first in class c-Myc inhibitor program, expected to enter clinical trails in 2021.

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research, clinical studies and highlights the work of the best minds in research and medicine from institutions all over the world.